Windtree Therapeutics Inc
NASDAQ:WINT

Watchlist Manager
Windtree Therapeutics Inc Logo
Windtree Therapeutics Inc
NASDAQ:WINT
Watchlist
Price: 0.03 USD
Market Cap: 1m USD

Windtree Therapeutics Inc
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Windtree Therapeutics Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Windtree Therapeutics Inc
NASDAQ:WINT
Research & Development
-$16.3m
CAGR 3-Years
5%
CAGR 5-Years
-5%
CAGR 10-Years
5%
Abbvie Inc
NYSE:ABBV
Research & Development
-$8.8B
CAGR 3-Years
-10%
CAGR 5-Years
-8%
CAGR 10-Years
-8%
Gilead Sciences Inc
NASDAQ:GILD
Research & Development
-$5.8B
CAGR 3-Years
-2%
CAGR 5-Years
-1%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Research & Development
-$6.8B
CAGR 3-Years
-15%
CAGR 5-Years
-10%
CAGR 10-Years
-5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Research & Development
-$3.9B
CAGR 3-Years
-16%
CAGR 5-Years
-16%
CAGR 10-Years
-16%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Research & Development
-$5.2B
CAGR 3-Years
-16%
CAGR 5-Years
-15%
CAGR 10-Years
-13%
No Stocks Found

Windtree Therapeutics Inc
Glance View

Market Cap
1m USD
Industry
Biotechnology

Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company, which engages in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. The company is headquartered in Warrington, Pennsylvania and currently employs 33 full-time employees. The Company’s development programs are primarily focused on the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. Its Cardiovascular Program’s products candidates include Istaroxime, Oral SERCA2a Activators and Rostafuroxin. Its Pulmonary Program’s product candidates include Lyophilized KL4 Surfactant and AEROSURF (aerosolized KL4 surfactant based on ADS technology). The Company’s lead product candidate, istaroxime, is a dual-acting agent being developed to improve cardiac function in patients with acute heart failure (AHF) with a potentially differentiated safety profile from existing treatments. Istaroxime demonstrated significant improvement in both diastolic and systolic aspects of cardiac function and is under phase II clinical trials.

WINT Intrinsic Value
0.03 USD
Overvaluation 1%
Intrinsic Value
Price

See Also

What is Windtree Therapeutics Inc's Research & Development?
Research & Development
-16.3m USD

Based on the financial report for Mar 31, 2025, Windtree Therapeutics Inc's Research & Development amounts to -16.3m USD.

What is Windtree Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 10Y
5%

Over the last year, the Research & Development growth was -78%. The average annual Research & Development growth rates for Windtree Therapeutics Inc have been 5% over the past three years , -5% over the past five years , and 5% over the past ten years .

Back to Top